NZ590919A - Vaccine against hpv - Google Patents

Vaccine against hpv

Info

Publication number
NZ590919A
NZ590919A NZ590919A NZ59091909A NZ590919A NZ 590919 A NZ590919 A NZ 590919A NZ 590919 A NZ590919 A NZ 590919A NZ 59091909 A NZ59091909 A NZ 59091909A NZ 590919 A NZ590919 A NZ 590919A
Authority
NZ
New Zealand
Prior art keywords
vaccine
dose
hpv
vaccine against
against hpv
Prior art date
Application number
NZ590919A
Other languages
English (en)
Inventor
Dominique Descamps
Sandra Giannini
Nicolas Lecrenier
Jean Stephenne
Martine Anne Cecile Wettendorff
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of NZ590919A publication Critical patent/NZ590919A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
NZ590919A 2008-07-31 2009-07-29 Vaccine against hpv NZ590919A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8510108P 2008-07-31 2008-07-31
US17656109P 2009-05-08 2009-05-08
PCT/EP2009/059820 WO2010012780A1 (en) 2008-07-31 2009-07-29 Vaccine against hpv

Publications (1)

Publication Number Publication Date
NZ590919A true NZ590919A (en) 2012-10-26

Family

ID=41139260

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ590919A NZ590919A (en) 2008-07-31 2009-07-29 Vaccine against hpv

Country Status (26)

Country Link
US (1) US20110189229A1 (enExample)
EP (1) EP2318042B1 (enExample)
JP (1) JP6022159B2 (enExample)
KR (1) KR20110053340A (enExample)
CN (1) CN102159239A (enExample)
AU (1) AU2009275909A1 (enExample)
BR (1) BRPI0916732B1 (enExample)
CA (1) CA2732436C (enExample)
CO (1) CO6341567A2 (enExample)
DK (1) DK2318042T3 (enExample)
DO (1) DOP2011000031A (enExample)
EA (1) EA201170264A1 (enExample)
ES (1) ES2519490T3 (enExample)
HR (1) HRP20141063T1 (enExample)
IL (1) IL210977A0 (enExample)
MA (1) MA32554B1 (enExample)
MX (1) MX2011001218A (enExample)
NZ (1) NZ590919A (enExample)
PE (1) PE20110327A1 (enExample)
PL (1) PL2318042T3 (enExample)
PT (1) PT2318042E (enExample)
RS (1) RS53607B1 (enExample)
SI (1) SI2318042T1 (enExample)
SM (1) SMT201400170B (enExample)
WO (1) WO2010012780A1 (enExample)
ZA (1) ZA201100889B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2768172A1 (en) 2009-06-25 2010-12-29 Glaxosmithkline Biologicals S.A. Novel compositions
CN102178944A (zh) * 2010-09-17 2011-09-14 大连雅立峰生物制药有限公司 人乳头瘤病毒16和18型l1蛋白在昆虫细胞中的表达及应用
CN102229660B (zh) * 2011-05-25 2015-04-22 厦门大学 截短的人乳头瘤病毒33型l1蛋白
KR101559622B1 (ko) * 2012-07-30 2015-10-13 중앙대학교 산학협력단 인유두종바이러스 바이러스 유사입자의 고효율 정제방법
EP3191505A2 (en) * 2014-09-11 2017-07-19 Cadila Healthcare Limited Superior human papilloma virus antigens with superior immunological properties and vaccine containing it
US10063211B2 (en) 2016-02-03 2018-08-28 Qualcomm Incorporated Compact bypass and decoupling structure for millimeter-wave circuits
RU2628693C1 (ru) * 2016-11-10 2017-08-21 федеральное государственное бюджетное учреждение "Федеральный научно-исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации (ФГБУ "ФНИЦЭМ им. Н.Ф. Гамалеи" Минздрава России) РЕКОМБИНАНТНЫЙ ГЕН L1HPV16, РЕКОМБИНАНТНАЯ ПЛАЗМИДА pQE-L1/16, БЕЛОК L1HPV16 И ИХ ПРИМЕНЕНИЕ
US20210302427A1 (en) * 2020-03-31 2021-09-30 Shuhari Group, LLC Secure Immunity Information Transmission System And Network
KR20260109890A (ko) * 2024-01-04 2026-07-13 사이안백 엘엘씨 백신 조성물에 증가된 안정성을 제공하는 개선된 제형

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
EP1732598A4 (en) * 2003-12-31 2009-08-26 Pharmexa Inc TRIGGERING CELLULAR IMMUNE RESPONSES TO THE HUMAN PAPILLOVIRUS USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS
US7758866B2 (en) * 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
KR20070029254A (ko) * 2004-06-16 2007-03-13 글락소스미스클라인 바이오로지칼즈 에스.에이. Hpv 16과 hpv 18 및 적어도 hpv 31, 45 또는52로부터 선택된 또 다른 hpv 유형에 대한 백신
AR054259A1 (es) * 2005-04-26 2007-06-13 Glaxosmithkline Biolog Sa Vacuna contra virus de papiloma humano (hpv)

Also Published As

Publication number Publication date
SMT201400170B (it) 2015-01-15
DK2318042T3 (da) 2014-11-10
BRPI0916732B1 (pt) 2021-06-29
CO6341567A2 (es) 2011-11-21
CA2732436C (en) 2018-01-16
DOP2011000031A (es) 2011-02-28
WO2010012780A1 (en) 2010-02-04
EP2318042B1 (en) 2014-08-20
MA32554B1 (fr) 2011-08-01
KR20110053340A (ko) 2011-05-20
US20110189229A1 (en) 2011-08-04
CN102159239A (zh) 2011-08-17
PL2318042T3 (pl) 2015-02-27
MX2011001218A (es) 2011-03-15
AU2009275909A1 (en) 2010-02-04
JP6022159B2 (ja) 2016-11-09
BRPI0916732A2 (pt) 2017-01-31
RS53607B1 (sr) 2015-04-30
SI2318042T1 (sl) 2014-12-31
CA2732436A1 (en) 2010-02-04
EP2318042A1 (en) 2011-05-11
PT2318042E (pt) 2014-11-05
JP2011529475A (ja) 2011-12-08
PE20110327A1 (es) 2011-06-29
IL210977A0 (en) 2011-04-28
HRP20141063T1 (hr) 2015-01-02
ES2519490T3 (es) 2014-11-07
ZA201100889B (en) 2012-04-25
EA201170264A1 (ru) 2011-08-30

Similar Documents

Publication Publication Date Title
EA201170264A1 (ru) Вакцина против hpv
MD4430B1 (ro) Compoziţii şi metode de tratament al hepatitei virale C
NZ606993A (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
WO2018005519A3 (en) Cancer treatment combinations
EP2444103A4 (en) VACCINE AGAINST NUTRITIONAL CANCER
HK1198703A1 (en) Hpv chimaeric particle
NZ597378A (en) Treatment of multiple sclerosis with laquinimod
NZ589445A (en) Rasagiline for parkinson's disease modification
EP2216024A3 (en) Use of Ranolazine for the treatment of cardiovascular diseases
MX2012008652A (es) Terapias para tratar infeccion por virus de hepatitis c.
NZ601319A (en) Antiviral combinations involving (4r,12as)-n-[(2,4-difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2h-pyrido[1’,2’:4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide
IL182440A0 (en) Subtype-matched inactivated whole virus vaccines for treating patients with hiv infection
JP2011529475A5 (enExample)
WO2021156404A3 (en) Treatment of hpv-related diseases
NZ598465A (en) Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin
WO2010045431A3 (en) Dry powder formulations, vaccines and methods
NZ588655A (en) Treatment of hepatitis c virus infections with telaprevir (vx-950) in patients non-responsive to treatment with pegylated interfer0n-alpha-2a/2b and ribavirin
JP2013523886A5 (enExample)
PL1778209T3 (pl) Sposoby i kompozycje do doustnego dostarczania FTS
WO2005016246A3 (en) Modified viral particles with immunogenic properties and reduced lipid content useful for treating and preventing infectious diseases
WO2010041889A3 (en) Pharmaceutical composition for preventing or treating chronic obstructive pulmonary disease
CN103096885A (zh) 不饱和脂肪酸用于抑制病毒复制和/或感染的用途
CY1115704T1 (el) Εμβολιο κατα του hpv
Vierling et al. High Efficacy at Lower Doses of MK-5172 25 mg and 50 mg Daily for 12 Weeks in HCV Genotype (G) 1 Treatment-Naive Non-cirrhotic Patients: 1123
CN201949352U (zh) 便捷服药器

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 29 JUL 2016 BY THOMSON REUTERS

Effective date: 20130719

LAPS Patent lapsed